20:22 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
19:01 , May 8, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Three cyclic peptide-based inhibitors of KDM4A , KDM4B and KDM4C could be useful for probing the role of the enzymes in cancer. Screening of a library of thioether-based macrocycles in vitro identified...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lysine-specific demethylase 4A (KDM4A; JMJD2A); KDM4B (JMJD2B) Cell culture studies suggest inhibiting KDM4A and KDM4B could help treat prostate cancer. In human prostate...
07:00 , May 23, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Heat shock protein 90 (Hsp90); lysine-specific demethylase 4B (KDM4B; JMJD2B) Cell culture studies suggest KDM4B activity could be reduced by blocking Hsp90. High KDM4B...